60 Degrees Pharmaceuticals Net Income

The latest net income for SXTP is $-8.1M as of June 2026. That compares with $-7.8M in the prior-year period — down 4.1% year over year. That is below the sector sector average of $90M. Investors often review this figure alongside 60 Degrees Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, SXTP's net income moved from $-7.8M to $-8.1M — a 4.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 60 Degrees Pharmaceuticals's operating scale or balance-sheet position.

Against its sector companies, SXTP currently prints $-8.1M for net income, while the sector average sits near $90M. That is roughly 109.0% below the sector mean. Large gaps often invite a closer look at 60 Degrees Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $-8.1M for SXTP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $90M. Explore the charts below for those layers of context.

After noting SXTP's net income ($-8.1M), review year-over-year change from $-7.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.